Trial site
UNC Health Cancer Care Wakefield
Raleigh, North Carolina 27614, United StatesNot linked to an institution yet
- 12running trials
- 1closed trial
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 2/33 trials
- Phase 21 trial
- Status
- Active, not recruiting9 trials
- Recruiting3 trials
- Completed1 trial
- Lead sponsor
- NRG Oncology5 trials
- National Cancer Institute (NCI)4 trials
- Alliance for Clinical Trials in Oncology2 trials
- SWOG Cancer Research Network2 trials
Running trials
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Elizabeth C. Dees (principal investigator)
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Yara Abdou (principal investigator)
Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572· Phase 2· SWOG Cancer Research Network· Source
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Source
Contact: Marie Wood, MD
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· Phase 2/3· NRG Oncology· Source
Contact: Ranjit Joseph (principal investigator)
Active, not recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· Phase 3· NRG Oncology· Source
Active, not recruiting
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· Phase 3· NRG Oncology· Source
Active, not recruiting
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· Phase 2/3· SWOG Cancer Research Network· Source
Contact: Jennifer Beeler
Active, not recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
NCT00843882· Phase 3· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error